Lista de obras - Olivier Christophe - Dominio Público Uruguay

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

artículo científico publicado en 2017

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

artículo científico publicado en 2018

A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

artículo científico publicado en 2016

A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor

artículo científico publicado en 2012

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

artículo científico publicado en 2007

Abnormal proteolytic processing of von Willebrand factor Arg611 Cys and Arg611His

artículo científico publicado en 1997

Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia

artículo científico publicado en 2013

Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa

scientific article published on 16 May 2008

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

artículo científico publicado en 2014

Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.

artículo científico publicado en 2015

Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib

artículo científico publicado en 1992

Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis

artículo científico publicado en 2016

Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain ⬇️

artículo científico publicado el 2 de enero de 1998

Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.

artículo científico publicado en 1996

Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

artículo científico publicado en 2020

Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

artículo científico publicado en 2006

Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695.

artículo científico publicado en 1996

Characterization of the interaction between von Willebrand factor and osteoprotegerin

artículo científico publicado en 2007

Clearance of von Willebrand factor

artículo científico publicado en 2008

Clearance of von Willebrand factor.

artículo científico

Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance

artículo científico publicado en 2012

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions

artículo científico publicado en 2017

Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants

artículo científico publicado en 2008

Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.

artículo científico publicado en 1994

Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

artículo científico publicado en 2017

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

artículo científico publicado en 2017

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

artículo científico publicado en 2014

Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

artículo científico publicado en 2012

Favourable progression of acquired hemophilia-associated bullous pemphigoid.

artículo científico publicado en 2009

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

artículo científico publicado en 2001

Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor

artículo científico publicado en 2012

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

artículo científico publicado en 2011

In vivo analysis of the role of O-glycosylations of von Willebrand factor.

artículo científico publicado en 2012

Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.

artículo científico publicado en 1994

LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex.

artículo científico publicado en 2016

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

artículo científico publicado en 2016

Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates

artículo científico publicado en 2014

Macrophage LRP1 contributes to the clearance of von Willebrand factor.

artículo científico publicado en 2012

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X.

artículo científico publicado en 2015

Macrophage scavenger-receptor SR-AI contributes to the clearance of von Willebrand factor

artículo científico publicado en 2018

Mouse models to study von Willebrand factor structure-function relationships in vivo

artículo científico publicado en 2009

Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.

artículo científico publicado en 2010

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

artículo científico publicado en 2013

Network-based analysis of omics data: the LEAN method

artículo científico publicado en 2016

P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor

scientific article published on 22 August 2006

Paraoxonase-1 expression is up-regulated in Down syndrome fetal liver.

artículo científico publicado en 2006

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

artículo científico publicado en 2010

Role of the alpha-helix 163-170 in factor Xa catalytic activity

scientific article published on 28 August 2007

Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.

artículo científico publicado en 2015

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

artículo científico publicado en 2016

Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.

artículo científico publicado en 2009

The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673

artículo científico publicado en 1991

The disappearing act of factor VIII.

artículo científico publicado en 2008

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

artículo científico publicado en 2013

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant

artículo científico publicado en 2013

Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.

artículo científico publicado en 2012

Two residues in the activation peptide domain contribute to the half-life of factor X in vivo

artículo científico publicado en 2010

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.

artículo científico publicado en 2013

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

artículo científico publicado en 2015

von Willebrand factor clearance does not involve proteolysis by ADAMTS-13

scientific article published on 01 October 2010

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

artículo científico publicado en 2013

von Willebrand factor: the old, the new and the unknown.

artículo científico

Lista de obras de Olivier Christophe

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation

A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

Abnormal proteolytic processing of von Willebrand factor Arg611 Cys and Arg611His

Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia

Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.

Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib

Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis

Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain ⬇️

Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.

Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications

Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695.

Characterization of the interaction between von Willebrand factor and osteoprotegerin

Clearance of von Willebrand factor

Clearance of von Willebrand factor.

Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions

Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants

Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.

Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Favourable progression of acquired hemophilia-associated bullous pemphigoid.

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.

LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex.

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates

Macrophage LRP1 contributes to the clearance of von Willebrand factor.

Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X.

Macrophage scavenger-receptor SR-AI contributes to the clearance of von Willebrand factor

Mouse models to study von Willebrand factor structure-function relationships in vivo

Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Network-based analysis of omics data: the LEAN method

P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor

Paraoxonase-1 expression is up-regulated in Down syndrome fetal liver.

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Role of the alpha-helix 163-170 in factor Xa catalytic activity

Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.

The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673

The disappearing act of factor VIII.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant

Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.

Two residues in the activation peptide domain contribute to the half-life of factor X in vivo

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions.

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

von Willebrand factor clearance does not involve proteolysis by ADAMTS-13

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

von Willebrand factor: the old, the new and the unknown.